Lilly(Eli) (LLY) P/E (2013 - 2026)
Lilly(Eli) (LLY) P/E from Apr 1, 2013 to Jul 20, 2026. The TTM Lilly(Eli) (LLY) P/E is 48.03. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
P/E
Annual P/E change of Lilly(Eli) (LLY)
| Year | P/E | Change |
|---|---|---|
| 2026 | 48.03 | -25.47% |
| 2025 | 64.45 | -43.26% |
| 2024 | 113.59 | -2.56% |
| 2023 | 116.57 | +91.18% |
| 2022 | 60.98 | +23.18% |
| 2021 | 49.50 | +71.93% |
| 2020 | 28.79 | +81.13% |
| 2019 | 15.90 | -64.79% |
| 2018 | 45.14 | +12.97% |
| 2017 | 39.96 | +41.87% |
| 2016 | 28.17 | -23.62% |
| 2015 | 36.88 | +57.41% |
| 2014 | 23.43 | +67.82% |
| 2013 | 13.96 | N/A |
Comparison Lilly(Eli) (LLY) P/E with competitors
Lilly(Eli) (LLY) P/E is 48.03.
| Ticker | Name | P/E | Upside |
|---|---|---|---|
| GRFS | Grifols SA | 10.11 | -78.95% |
| PFE | Pfizer Inc | 11.65 | -75.74% |
| NVO | Novo Nordisk | 11.79 | -75.45% |
| GSK | GSK Plc | 12.10 | -74.80% |
| SNY | Sanofi | 12.12 | -74.76% |
| BMY | Bristol-Myers Squibb Company | 13.82 | -71.23% |
| OGN | Organon & Company | 14.33 | -70.17% |
| BIIB | Biogen Inc | 17.41 | -63.76% |
| GILD | Gilead Sciences Inc | 17.75 | -63.06% |
| NVS | Novartis AG | 21.60 | -55.04% |
| JNJ | Johnson & Johnson | 22.09 | -54.01% |
| AMGN | AMGEN Inc | 24.75 | -48.47% |
| MRK | Merck & Co Inc | 26.93 | -43.94% |
| AZN | Astrazeneca plc | 28.44 | -40.78% |
| ABBV | Abbvie Inc | 139.08 | +189.56% |